Alexandria Pharmaceuticals results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit18.2 millionEGP · −50.9% vs the same period a year earlier
Total assets923 millionEGP · +5.5% vs the same period a year earlier
Shareholders' equity660 millionEGP · +4.8% vs the same period a year earlier
Operating cash flow-3.16 millionEGP · −102.8% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q4 2023 was about 18.2 million EGP, down −50.9% from 37.06 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 923 million EGP, and shareholders' equity about 660 million EGP.
- Operating cash flow for Q4 2023 was negative at 3.16 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit18.2 million37.06 million−50.9%
Gross profit70.37 million271 million−74.0%
Total assets923 million875 million+5.5%
Total liabilities263 million245 million+7.2%
Shareholders' equity660 million630 million+4.8%
Total liabilities and equity923 million875 million+5.5%
Operating cash flow-3.16 million111 million−102.8%
Investing cash flow-22.35 million-2.15 million−941.1%
Financing cash flow-8.08 million-10.14 million+20.3%
Net change in cash-33.6 million98.99 million−133.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy